UKE Homepage
DE
/2024-relaunch/logo/logo_ucc_hamburg.svg){kind=logo}
Myeloma Consultation
If multiple myeloma or plasmacytoma has been diagnosed or there is suspicion of such a condition, we offer comprehensive counseling, precise diagnostics, and an individualized treatment plan in our specialized multiple myeloma consultation clinic.
You are also welcome to contact us at any time for an independent second opinion—for example, regarding questions about starting treatment or changing your therapy.
Multiple Myeloma is a cancer that originates from certain immune system cells called plasma cells. These cells are primarily located in the bone marrow. Normally, plasma cells produce antibodies to fight infections. However, in multiple myeloma, these cells multiply abnormally and uncontrollably. This can disrupt the body's balance and lead to various symptoms, such as bone pain, weakened immune function, or impaired kidney function.
Because the disease is so complex, treatment by specialized experts and careful, personalized care are especially important.
Our main goal is to find the best approach for you, together. In our consultation clinic, we take the time to address all your questions and to clearly discuss the various treatment options.
Our treatment offerings include:
- All proven standard therapies: We utilize all modern and approved medications for the treatment of multiple myeloma.
- Autologous stem cell transplantation: An established intensive therapy in which we use your own previously collected (autologous) blood stem cells to reconstruct the bone marrow after high-dose chemotherapy.
- Innovative clinical trial therapies: As a university hospital specializing in “Multiple Myeloma,” we can offer you participation in clinical studies whenever available in each treatment situation. This provides you with access to the most modern treatment approaches that are not yet widely available.
- Cutting-edge cell therapies (CAR T-cell therapy): We are one of Germany’s specialized centers for treatments using so-called CAR T-cells. In this therapy, your own immune cells are genetically modified in the laboratory to specifically recognize and destroy myeloma cells.
Contact
To register for a consultation, please use our contact form or the contact details of the central entry point.
Office Hours
You can find the current office hours in the office hours overview at our central entry point.
Our multiple myeloma center is led by Prof. Dr. Katja Weisel, a nationally and internationally recognized expert in multiple myeloma. The co-leader of the center is Dr. Lisa Leypoldt.
Together, they oversee the GMMG-CONCEPT study, which is the first academic trial specifically focused on the treatment of high-risk myeloma. Other areas of their work include treating patients with multiple myeloma and impaired kidney function, as well as specific diagnostics such as testing for minimal residual disease (MRD). Additionally, they are involved in developing new medications for multiple myeloma.
Additionally, Prof. Weisel is a co-author of the German Onkopedia guideline for the treatment of multiple myeloma and is actively involved in numerous scientific committees. She is a member of the International Myeloma Working Group (IMWG), the European Myeloma Network (EMN), the steering committee of the German Speaking Myeloma Multicenter Group (GMMG), and the Medical Advisory Board of the German Myeloma Patients Association (Myelom Deutschland e.V.).
With over 100 scientific publications, Prof. Weisel is among the leading voices in myeloma research and makes significant contributions to the advancement of modern treatment strategies.
Together with her medical colleague, Dr. Lisa Leypoldt, Prof. Weisel has been leading the clinical and translational myeloma center at UKE since April 2019. Additionally, there are collaborations with scientists at UKE and national and international research groups for clinical, experimental, and basic research on multiple myeloma.
In patient care as well as in the planning of scientific and research projects, we work closely with the myeloma support group Hamburg.
/2024-relaunch/bilder/leypoldt-lisa-20241112-10_st_plus_576x1.jpg)
Award Laurels for Young Scientist
Dr. Lisa Leypoldt
The young scientist, who initiated a clinical study on multiple myeloma at UKE, has been awarded three prestigious research prizes. Since 2019, she has been studying high-risk myeloma, most recently with a scholarship at Harvard Medical School in Boston.
Head of the Consultation Clinic
/2024-relaunch/bilder/kontaktbild-katja-weisel-wei%C3%9F_st_plus_300x1.jpg)
Katja Weisel
Multiple Myeloma
/2024-relaunch/bilder/kontaktbild-lisa-leypoldt_st_plus_300x1.jpg)
Lisa Leypoldt
Multiple Myeloma
/2024-relaunch/bilder/ucc-hamburg-platzhalter-person-hell_st_plus_300x1.jpg)
Winfried Alsdorf
CAR T-Cell Therapy
Resident Physicians
/2024-relaunch/bilder/kontaktbild-leandra-bartke_st_plus_300x1.png)
Leandra Bartke
/2024-relaunch/bilder/kontaktbild-maximilian-al-bazaz_st_plus_300x1.jpg)
Maximilian Al-Bazaz
/2024-relaunch/bilder/kontaktbild-jule-cecilia-artzenroth_st_plus_300x1.jpg)
Jule Cecilia Artzenroth
/2024-relaunch/bilder/kontaktbild-ricardo-kosch_st_plus_300x1.jpg)
Ricardo Kosch
/2024-relaunch/bilder/kontaktbild-leon-cords_st_plus_300x1.png)
/2024-relaunch/bilder/kontaktbild-marie-harzer_st_plus_300x1.png)
/2024-relaunch/bilder/kontaktbild-christoph-schaefers_st_plus_300x1.jpg)
Christoph Schaefers
Do you have any questions or would you like to make an appointment? Here you will find our contact details for UCC Hamburg.
MehrThe UCC Hamburg newsletter provides information about all of the network's events and the latest developments.
MehrHelp us improve care for cancer patients. Whether as a one-time donation, standing order, or even a bequest, we appreciate every contribution.